Lucid Diagnostics Posts $1.3M in Q1 EsoGuard Revenue, Secures $17M Offering
Lucid Diagnostics recorded $1.3M in Q1 2026 EsoGuard revenue, processing 3,177 tests. It raised $17M in a public offering to end Q1 with $45M pro forma cash and runway into 2027, and upcoming clinical guidelines will endorse EsoGuard and EsoCheck as the only non-endoscopic tests with high certainty.
1. Q1 Financial Results
Lucid Diagnostics recognized $1.3M in EsoGuard revenue during Q1 2026 and processed 3,177 tests, reflecting growing commercial momentum for its esophageal DNA testing platform.
2. Balance Sheet and Cash Runway
The company completed an underwritten public offering that raised $17M, ending Q1 with $45M in pro forma cash and extending its operational runway into 2027.
3. Clinical Guidelines and Market Adoption
Upcoming clinical practice guideline updates will endorse EsoGuard and EsoCheck as the only non-endoscopic tests with high certainty evidence, positioning Lucid for broader market adoption upon implementation.